Phase I study of Vidaza [azacitidine] and Velcade (bortezomib) in acute myeloid leukaemia.
Phase of Trial: Phase I
Latest Information Update: 24 Aug 2017
At a glance
- Drugs Azacitidine (Primary) ; Bortezomib (Primary)
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 30 May 2008 Status changed from initiated to recruiting, reported by ClinicalTrials.gov.
- 28 Mar 2008 New trial record.